• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • 0 CME Hours
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
#Grand Rounds

The HPV Vaccine Leads to a Reduction in Cervical Precancers in Young Women in the U.S.

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • High-grade cervical lesions (CIN2+) are used to monitor HPV vaccine impact, since they develop much more quickly after infection
  • McClung et al. (MMWR, 2019) used data from the Human Papillomavirus Vaccine Impact Monitoring Project (HPV-IMPACT) to assess the impact of the HPV vaccination program
  • The following is the first estimate of the number of CIN2+ cases in the U.S. based on population since introduction of the HPV vaccine

METHODS:

  • Data review and analysis (2008 to 2016)
    • Data set: HPV-IMPACT
    • A population-based CIN2+ surveillance system
  • Data analysis
    • Age-specific rates applied to U.S. population data to estimate the total number of CIN2+ cases

RESULTS:

  • An estimated 76% of CIN2+ cases were attributable to HPV types targeted by the vaccine currently used in the US (9-valent HPV vaccine)
  • The number of CIN2+ cases diagnosed in women aged 18–29 years decreased from 2008 to 2016
    • 2008: ~216,000 (95% CI, 194,000–241,000)
    • 2016: ~196,000 (95% CI, 176,000–221,000)
  • From 2008 to 2016, the rate of CIN2+ per 100,000 women in the US
    • Declined significantly in women aged 18–19 years and 20–24 years
    • Increased significantly in women aged 40–64 years

CONCLUSION:

  • Rates of cervical precancers have declined in younger women since the introduction of the vaccine
  • A majority of CIN2+ cases diagnosed are attributable to HPV types that the vaccine targets
  • These changes are likely due to updated cervical cancer screening and management recommendations, and primary prevention through HPV vaccination
  • Increasing coverage of the vaccine in females at the routine age of 11-12 years and catch-up vaccination through women 26 years of age will likely contribute to a further reduction in cervical precancers

Learn More – Primary Sources:

Estimated Number of Cases of High-Grade Cervical Lesions Diagnosed Among Women — United States, 2008 and 2016

Now You Can Get ObG Clinical Research Summaries Direct to Your Phone, with ObGFirst

Learn More  »

image_pdfFavoriteLoadingFavorite
< Previous
All #Grand Rounds Posts
Next >

Related ObG Topics:

HPV Vaccine Recommendations Including Guidance for Ages 27 to 45
Gardasil Now FDA Approved for Individuals 27 to 45 Years Old
HPV Vaccines: Cochrane Reviews Looks at the Evidence with Multi-Year Follow-Up

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • #Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

ObG Library

  • Hysteroscopy
  • Fertility
  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Log In to ObG First

Please log in to access OBGFirst and the 2T Ultrasound Atlas

Password Trouble?

Sign Up for ObGFirst

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!

ObG First Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site